Ultromics
Generated by Meeveem AI
"AI powered echocardiography platform detecting heart failure with clinical precision"
Oxford
•51 - 250 Employees
•Digital Health
About Ultromics
Ultromics provides clinically validated AI that analyzes routine echocardiograms to detect heart failure with preserved ejection fraction and cardiac amyloidosis. The EchoGo platform delivers diagnostic insights within 20 minutes with 90% sensitivity. Founded as an Oxford University spin out, the company holds four FDA clearances and processes over 430,000 clinical cases globally. Heart failure affects 64 million people worldwide, yet HFpEF often goes undiagnosed. By integrating with existing healthcare infrastructure, Ultromics enables faster, more precise diagnoses that improve patient outcomes while reducing the burden of untreated cases and unnecessary procedures on healthcare systems.
76
Team Members
2017
Founded
Digital Health
Sector
Hybrid
Work Environment
Our Vision
A world where every patient with heart failure is detected early through accessible, clinically validated AI, leading to timely treatment, better outcomes, and reduced burden on global healthcare systems.
Our Mission
At Ultromics, our mission is to make heart failure detection easier for providers and prognosis better for patients through clinically validated AI that delivers critical diagnostic information with minimal added risks or costs.